| Justin J Raatz, Dpm Pllc | |
|
500 E Court Ave, Suite 314, Des Moines, IA 50309-2057 | |
| (308) 660-5407 | |
| (515) 883-2692 |
| Full Name | Justin J Raatz, Dpm Pllc |
|---|---|
| Type | Facility |
| Speciality | Podiatrist - Foot & Ankle Surgery |
| Location | 500 E Court Ave, Des Moines, Iowa |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174976948 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | 082885 (Iowa) | Primary |
| Provider Name | Justin J Raatz |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1306175104 PECOS PAC ID: 8022273861 Enrollment ID: I20160913002176 |
News Archive
The fight over marijuana - for medical purposes or not - simmers in California, where the drug is treated casually and a large medical marijuana dispensary is challenging the federal government's closure of its business.
The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks has increased 58% in its first two months of reporting. CI Index gain was paced by the 233% share price improvement of ImmunoCellular Theraputics, Inc. (IMUC.OB) under the leadership of CEO Manish Singh, Ph. D.
The American Association of Colleges of Pharmacy will honor Robert L. Talbert, Pharm.D., B.S., professor of pharmacotherapy in the College of Pharmacy at The University of Texas at Austin, for his excellence as a teacher, his outstanding achievements as an author and mentor, and his overall impact on pharmacy education and the profession.
Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.
Technicians are needed to help hospitals develop and use electronic health records. Other reports look at the efforts to develop secure and efficient digital records.
› Verified 4 days ago
| Provider Name | Steven J Ostiguy |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1548611064 PECOS PAC ID: 7719211242 Enrollment ID: I20190702003311 |
News Archive
The fight over marijuana - for medical purposes or not - simmers in California, where the drug is treated casually and a large medical marijuana dispensary is challenging the federal government's closure of its business.
The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks has increased 58% in its first two months of reporting. CI Index gain was paced by the 233% share price improvement of ImmunoCellular Theraputics, Inc. (IMUC.OB) under the leadership of CEO Manish Singh, Ph. D.
The American Association of Colleges of Pharmacy will honor Robert L. Talbert, Pharm.D., B.S., professor of pharmacotherapy in the College of Pharmacy at The University of Texas at Austin, for his excellence as a teacher, his outstanding achievements as an author and mentor, and his overall impact on pharmacy education and the profession.
Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.
Technicians are needed to help hospitals develop and use electronic health records. Other reports look at the efforts to develop secure and efficient digital records.
› Verified 4 days ago
| Provider Name | Kelsey J Millonig |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1194176297 PECOS PAC ID: 8921421629 Enrollment ID: I20210601000733 |
News Archive
The fight over marijuana - for medical purposes or not - simmers in California, where the drug is treated casually and a large medical marijuana dispensary is challenging the federal government's closure of its business.
The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks has increased 58% in its first two months of reporting. CI Index gain was paced by the 233% share price improvement of ImmunoCellular Theraputics, Inc. (IMUC.OB) under the leadership of CEO Manish Singh, Ph. D.
The American Association of Colleges of Pharmacy will honor Robert L. Talbert, Pharm.D., B.S., professor of pharmacotherapy in the College of Pharmacy at The University of Texas at Austin, for his excellence as a teacher, his outstanding achievements as an author and mentor, and his overall impact on pharmacy education and the profession.
Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.
Technicians are needed to help hospitals develop and use electronic health records. Other reports look at the efforts to develop secure and efficient digital records.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Justin J Raatz, Dpm Pllc 500 E Court Ave Ste 314, Des Moines, IA 50309-2057 Ph: (515) 282-6067 | Justin J Raatz, Dpm Pllc 500 E Court Ave, Suite 314, Des Moines, IA 50309-2057 Ph: (308) 660-5407 |
News Archive
The fight over marijuana - for medical purposes or not - simmers in California, where the drug is treated casually and a large medical marijuana dispensary is challenging the federal government's closure of its business.
The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks has increased 58% in its first two months of reporting. CI Index gain was paced by the 233% share price improvement of ImmunoCellular Theraputics, Inc. (IMUC.OB) under the leadership of CEO Manish Singh, Ph. D.
The American Association of Colleges of Pharmacy will honor Robert L. Talbert, Pharm.D., B.S., professor of pharmacotherapy in the College of Pharmacy at The University of Texas at Austin, for his excellence as a teacher, his outstanding achievements as an author and mentor, and his overall impact on pharmacy education and the profession.
Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.
Technicians are needed to help hospitals develop and use electronic health records. Other reports look at the efforts to develop secure and efficient digital records.
› Verified 4 days ago
Dr. Jarrod Alexander Smith, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 3200 Grand Ave, Des Moines, IA 50312 Phone: 515-271-1731 | |
Dr. David Albert Yount, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 2459 E Euclid Ave, Suite A, Des Moines, IA 50317 Phone: 515-262-5856 Fax: 515-262-6446 | |
Katrina Almeida, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1415 Woodland Ave, Suite 140, Des Moines, IA 50309 Phone: 515-241-4076 | |
Ronald P Belin, DPM Podiatrist Medicare: Medicare Enrolled Practice Location: 1801 Hickman Rd, Des Moines, IA 50314 Phone: 515-282-2200 | |
James Michael Mahoney, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 3200 Grand Ave, Des Moines, IA 50312 Phone: 515-271-1731 Fax: 515-271-1692 | |
John David Bennett, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 3200 Grand Ave, Des Moines, IA 50312 Phone: 515-271-1731 Fax: 515-271-1692 | |
Sean T Grambart, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 3200 Grand Ave, Des Moines, IA 50312 Phone: 515-271-1700 |